Sign in

Stacy Koo

Research Analyst at TV Co

Stacy Koo's questions to KalVista Pharmaceuticals (KALV) leadership

Stacy Koo's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

Stacy Koo inquired about the mechanics of the quick start program, the process for prior authorizations and medical exemptions, and the expected timeline for patients to receive paid drug. She also asked about observed prescribing patterns, the composition of the 4,000-member patient database, and the typical cadence of clinician office visits for new prescriptions.

Answer

Nicole Sweeny, Chief Commercial Officer, explained that the quick start program provides immediate no-charge access while KalVista works with physician offices for medical exceptions, with a second shipment provided by KalVista if needed. She noted the patient database is clustered around onboarding and tier two physicians, supported by in-person education. Prescriber visits vary, with some physicians requiring a visit, some using telehealth, and others not requiring a visit for therapy prescription.

Ask Fintool Equity Research AI

Stacy Koo's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

Stacy Koo asked for further details on the quick start program, including the process for prior authorizations and medical exemptions, expectations for timing to paid drug, and how patient start forms translate to paid prescriptions. She also inquired about prescribing patterns, the composition of the 4,000-strong patient/caregiver database, and the expected cadence of clinician visits for new prescriptions.

Answer

Nicole Sweeny, Chief Commercial Officer, explained that the quick start program provides immediate, no-charge access to EKTERLY while KalVista works with physician offices to secure paid access via medical exceptions, with a second shipment provided by KalVista if needed. She noted that formal coverage policies typically take up to six months to establish. Sweeny also highlighted that the patient database growth was encouraging, with members clustered around onboarding and tier two physicians, and that prescribing physicians varied in requiring in-person or telehealth visits. Ben Palleiko, CEO, clarified some audio issues during the response.

Ask Fintool Equity Research AI